10.19
price up icon0.79%   0.08
 
loading
Viatris Inc stock is traded at $10.19, with a volume of 7.01M. It is up +0.79% in the last 24 hours and down -3.41% over the past month. Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$10.11
Open:
$10.18
24h Volume:
7.01M
Relative Volume:
0.74
Market Cap:
$11.88B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-3.2145
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
+7.04%
1M Performance:
-3.41%
6M Performance:
+24.88%
1Y Performance:
-10.85%
1-Day Range:
Value
$10.06
$10.38
1-Week Range:
Value
$9.465
$10.38
52-Week Range:
Value
$6.85
$13.55

Viatris Inc Stock (VTRS) Company Profile

Name
Name
Viatris Inc
Name
Phone
(724) 514-1465
Name
Address
1000 MYLAN BOULEVARD, CANONSBURG
Name
Employee
32,000
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
VTRS's Discussions on Twitter

Compare VTRS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
VTRS
Viatris Inc
10.19 11.79B 14.33B -3.79B 1.84B -3.17
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
146.42 64.92B 9.39B 2.62B 2.22B 5.8121
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.60 45.60B 29.96B 957.25M 4.77B 0.2956
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
8.95 39.54B 14.26B 1.98B 2.47B 0.4327
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
20.01 23.00B 16.70B -157.13M 1.19B -0.155
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
453.07 20.06B 2.99B 1.21B 1.13B 25.06

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-06-25 Initiated Goldman Neutral
Jul-19-24 Resumed Jefferies Buy
Oct-23-23 Downgrade BofA Securities Neutral → Underperform
Jun-23-23 Downgrade Barclays Equal Weight → Underweight
Apr-24-23 Downgrade Barclays Overweight → Equal Weight
Feb-17-23 Downgrade BMO Capital Markets Outperform → Market Perform
Jan-27-23 Upgrade Jefferies Hold → Buy
Nov-10-22 Upgrade UBS Sell → Neutral
Nov-08-22 Upgrade Piper Sandler Underweight → Neutral
Oct-21-22 Resumed Jefferies Hold
Jun-14-22 Initiated UBS Sell
May-10-22 Downgrade Piper Sandler Neutral → Underweight
Mar-01-22 Downgrade BofA Securities Buy → Neutral
Mar-01-22 Downgrade Raymond James Outperform → Mkt Perform
Jun-15-21 Initiated Citigroup Neutral
Apr-07-21 Resumed RBC Capital Mkts Outperform
Mar-08-21 Downgrade Goldman Buy → Neutral
Mar-02-21 Downgrade JP Morgan Overweight → Neutral
Feb-26-21 Downgrade Wolfe Research Outperform → Peer Perform
Jan-05-21 Initiated Argus Hold
Dec-14-20 Initiated Bernstein Mkt Perform
View All

Viatris Inc Stock (VTRS) Latest News

pulisher
Oct 03, 2025

What analysts say about Viatris Inc stockRSI Overbought/Oversold & Small Entry Cost Trading - earlytimes.in

Oct 03, 2025
pulisher
Oct 02, 2025

Allergy Treatment Global Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, ALK - PharmiWeb.com

Oct 02, 2025
pulisher
Oct 02, 2025

Viatris to Report Third Quarter 2025 Financial Results on November 6, 2025 - BioSpace

Oct 02, 2025
pulisher
Oct 01, 2025

The Importance of a Global, Resilient Supply Chain to Access - CSRwire

Oct 01, 2025
pulisher
Oct 01, 2025

Relative strength of Viatris Inc. in sector analysisProduct Launch & Reliable Price Action Trade Plans - newser.com

Oct 01, 2025
pulisher
Oct 01, 2025

Acute Social Anxiety Disorder Market on Track for Major Expansion by 2034, According to DelveInsight | GlaxoSmithKline Plc, Viatris Inc, Johnson & Johnson, Novartis AG, Pfizer Inc, AstraZeneca Plc - Barchart.com

Oct 01, 2025
pulisher
Oct 01, 2025

Pharmaceutical Giant Viatris Schedules Q3 2025 Financial Results and Investor Conference Call for November 6 - Stock Titan

Oct 01, 2025
pulisher
Sep 29, 2025

Will Viatris Inc. stock continue dividend increasesMarket Performance Summary & Risk Controlled Swing Alerts - newser.com

Sep 29, 2025
pulisher
Sep 29, 2025

Viatris Inc. (VTRS) Stock Analysis: Exploring a Potential 20% Upside Amid High Dividend Yield - DirectorsTalk Interviews

Sep 29, 2025
pulisher
Sep 29, 2025

Quantitative breakdown of Viatris Inc. recent moveJuly 2025 Gainers & Low Drawdown Momentum Trade Ideas - newser.com

Sep 29, 2025
pulisher
Sep 28, 2025

Levi & Korsinsky Notifies Viatris Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineVTRS - 2822news.com

Sep 28, 2025
pulisher
Sep 28, 2025

What drives Viatris Inc stock priceBear Market Strategies & Free Unstoppable Trading Performance - earlytimes.in

Sep 28, 2025
pulisher
Sep 28, 2025

What drives Viatris Inc VIA stock priceStock Buyback Updates & Build Wealth With Expert Timing Advice - earlytimes.in

Sep 28, 2025
pulisher
Sep 27, 2025

What analysts say about Viatris Inc VIA stockCandlestick Trading Patterns & Identify Breakout Stocks - earlytimes.in

Sep 27, 2025
pulisher
Sep 27, 2025

Viatris Inc VIA Stock Analysis and ForecastFederal Reserve Announcements & Explosive Profit Growth - Early Times

Sep 27, 2025
pulisher
Sep 26, 2025

Is Viatris Stock Underperforming the Nasdaq? - MSN

Sep 26, 2025
pulisher
Sep 25, 2025

Viatris: Indore Plant Could Boost 2026 Numbers (NASDAQ:VTRS) - Seeking Alpha

Sep 25, 2025
pulisher
Sep 24, 2025

Viatris Nixes Biogen's Extra 1-Year Protection Over MS Drug - Law360

Sep 24, 2025
pulisher
Sep 23, 2025

Viatris Inc. (VTRS) Gains FDA Approval for First Generic Iron Sucrose Injection - Insider Monkey

Sep 23, 2025
pulisher
Sep 23, 2025

How Viatris’ (VTRS) Removal from the FTSE All-World Index Could Affect Investor Sentiment - Sahm

Sep 23, 2025
pulisher
Sep 21, 2025

Viatris Inc.(NasdaqGS: VTRS) dropped from FTSE All-World Index - MarketScreener

Sep 21, 2025
pulisher
Sep 21, 2025

Viatris (VTRS): Evaluating Valuation Following FDA Nod for Generic Iron Sucrose and Pipeline Progress - Sahm

Sep 21, 2025
pulisher
Sep 20, 2025

Street Watch: Is Viatris Inc a defensive stock2025 Technical Patterns & Weekly Stock Performance Updates - خودرو بانک

Sep 20, 2025
pulisher
Sep 20, 2025

Fundamentals Check: Is now the right time to enter Viatris IncJuly 2025 Spike Watch & Target Return Focused Picks - khodrobank.com

Sep 20, 2025
pulisher
Sep 20, 2025

Will Viatris Inc. see short term momentum2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com

Sep 20, 2025
pulisher
Sep 19, 2025

Trading Recap: Can Viatris Inc. withstand a market correctionInsider Selling & Precise Trade Entry Recommendations - khodrobank.com

Sep 19, 2025
pulisher
Sep 19, 2025

Forecast Cut: How do insiders feel about Viatris IncWeekly Stock Report & Long Hold Capital Preservation Tips - خودرو بانک

Sep 19, 2025
pulisher
Sep 19, 2025

Short Covering: Will Viatris Inc stock hit new highs in YEAROil Prices & Free Verified High Yield Trade Plans - khodrobank.com

Sep 19, 2025
pulisher
Sep 18, 2025

Viatris pulls generic for Teva’s Trisenox in EU - MSN

Sep 18, 2025
pulisher
Sep 18, 2025

VIX Spike: Can Viatris Inc ride the EV waveRisk Management & Reliable Momentum Entry Alerts - خودرو بانک

Sep 18, 2025
pulisher
Sep 17, 2025

Viatris Inc. (VTRS) Enters $515M IV Iron Market With FDA Green Light - MSN

Sep 17, 2025
pulisher
Sep 17, 2025

Viatris (VTRS) Recovers Slightly But Struggles Amid Market Conce - GuruFocus

Sep 17, 2025
pulisher
Sep 17, 2025

Viatris rises after a steep seven-day slide - MSN

Sep 17, 2025
pulisher
Sep 17, 2025

Day 7 of Loss Streak for Viatris Stock with -9% Return (vs. -20% YTD) [9/16/2025] - Trefis

Sep 17, 2025
pulisher
Sep 16, 2025

Institution Moves: Can Viatris Inc ride the EV waveLong Setup & Daily Momentum Trading Reports - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Volatility Watch: Is Viatris Inc stock suitable for long term investing2025 Bull vs Bear & Weekly High Conviction Trade Ideas - خودرو بانک

Sep 16, 2025
pulisher
Sep 16, 2025

Market Moves: Is now the right time to enter Viatris IncJuly 2025 Price Swings & Low Risk High Reward Trade Ideas - khodrobank.com

Sep 16, 2025
pulisher
Sep 16, 2025

Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer - MSN

Sep 16, 2025
pulisher
Sep 16, 2025

Aug Swings: Is now the right time to enter Viatris IncJuly 2025 Spike Watch & Target Return Focused Picks - khodrobank.com

Sep 16, 2025
pulisher
Sep 15, 2025

Market Leaders: Can Viatris Inc. navigate macro headwindsQuarterly Profit Report & Consistent Return Strategy Ideas - خودرو بانک

Sep 15, 2025
pulisher
Sep 14, 2025

Viatris chief commercial officer Le Goff sells $72k in stock - Investing.com Nigeria

Sep 14, 2025
pulisher
Sep 12, 2025

Viatris chief commercial officer Le Goff sells $72k in stock By Investing.com - Investing.com South Africa

Sep 12, 2025
pulisher
Sep 12, 2025

Acute myocardial infarction Market Analysis: Epidemiology Insights, Therapies, Companies, by DelveInsight | Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, CeleCor Th - Barchart.com

Sep 12, 2025
pulisher
Sep 11, 2025

Real time scanner hits for Viatris Inc. explainedMarket Trend Review & Low Risk Profit Maximizing Plans - Newser

Sep 11, 2025
pulisher
Sep 10, 2025

Viatris Investors Face Skeptical Judges on Biosimilars Unit (1) - Bloomberg Law News

Sep 10, 2025

Viatris Inc Stock (VTRS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_specialty_generic RDY
$14.16
price up icon 0.64%
$52.54
price down icon 9.21%
$20.64
price up icon 0.83%
$137.03
price up icon 0.21%
$453.07
price up icon 2.17%
Cap:     |  Volume (24h):